...
首页> 外文期刊>Cardiovascular and Interventional Radiology: A Journal of Imaging in Diagnosis and Treatment >Lung radiofrequency ablation for the treatment of unresectable recurrent non-small-cell lung cancer after surgical intervention.
【24h】

Lung radiofrequency ablation for the treatment of unresectable recurrent non-small-cell lung cancer after surgical intervention.

机译:肺射频消融治疗外科手术后不可切除的复发性非小细胞肺癌。

获取原文
获取原文并翻译 | 示例

摘要

A retrospective evaluation was done of clinical utility of lung radiofrequency (RF) ablation in recurrent non-small-cell lung cancer (NSCLC) after surgical intervention.During May 2003 to October 2010, 44 consecutive patients (26 male and 18 female) received curative lung RF ablation for 51 recurrent NSCLC (mean diameter 1.7±0.9 cm, range 0.6 to 4.0) after surgical intervention. Safety, tumor progression rate, overall survival, and recurrence-free survival were evaluated. Prognostic factors were evaluated in multivariate analysis.A total of 55 lung RF sessions were performed. Pneumothorax requiring pluerosclerosis (n=2) and surgical suture (n=1) were the only grade 3 or 4 adverse events (5.5%, 3 of 55). During mean follow-up of 28.6±20.3 months (range 1 to 98), local tumor progression was found in 5 patients (11.4%, 5 of 44). The 1-, 3-, and 5-year overall survival rates were 97.7, 72.9, and 55.7%, respectively. The 1- and 3-year recurrence-free survival rates were 76.7 and 41.1%, respectively. Tumor size and sex were independent significant prognostic factors in multivariate analysis. The 5-year survival rates were 73.3% in 18 women and 60.5% in 38 patients who had small tumors measuring≤3 cm.Our results suggest that lung RF ablation is a safe and useful therapeutic option for obtaining long-term survival in treated patients.
机译:回顾性评估了外科手术后肺射频消融在复发性非小细胞肺癌(NSCLC)中的临床应用.2003年5月至2010年10月,连续44例患者(男26例,女18例)接受了治愈手术后51例复发性NSCLC(平均直径1.7±0.9 cm,范围0.6至4.0)的肺射频消融。评估了安全性,肿瘤进展率,总生存率和无复发生存率。在多因素分析中评估预后因素。共进行了55次肺部射频治疗。仅有3级或4级不良反应是需要胸膜硬化的气胸(n = 2)和手术缝合线(n = 1)(5.5%,3/55)。平均随访28.6±20.3个月(范围1至98),发现5例患者出现局部肿瘤进展(11.4%,44例中的5例)。 1年,3年和5年总生存率分别为97.7、72.9和55.7%。 1年和3年无复发生存率分别为76.7和41.1%。在多变量分析中,肿瘤大小和性别是独立的重要预后因素。肿瘤小于等于3 cm的18名女性的5年生存率分别为73.3%和38.例患者的60.5%。我们的结果表明,肺射频消融术是治疗患者获得长期生存的安全有效的治疗选择。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号